Official UK procurement notice
High Content Screening System
Authority: MEDICINES DISCOVERY CATAPULT LIMITED (Public body)
What is being bought
Published requirement descriptionThe Advanced Technologies team at the Medicines Discovery Catapult (MDC) is looking to expand its current advanced microscopy facility to support both our own growing needs and provide the UK SME community access to advanced molecular and cellular imaging.
MDC is aiming purchase a confocal High Content Screening (HCS) instrument based on an automated well-plate inverted microscope, together with confocal and widefield functionalities. It is crucial for the HCS system to be flexible and provide fast and high-resolution imaging of a wide range of experiments.
The instrument should be configured to enable the use of different sample formats (2D and 3D cell models, tissue sections, fixed and live-cell) and experimental types (drug dose responses, live-cell kinetic studies, phenotypic screening, RNA scope), using a large variety of well-plate formats and a wide range of fluorophores. In addition, the HCS instrument must be supplied with a high-end solution for high content image analysis, visualization and handling.
CPV: Laboratory, optical and precision equipments (excl. glasses)
The lotProcurement structure
single lot · value publishedLot #1AwardedPublished value£750,000
What it takes to wini
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Evaluation split and conditions of participation as published; the tender pack may add morei
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Published sub-criteria (13)
- Delivery: 3%
- Detailed Specification: 10%
- Imaging workflow, visualization, and image analysis: 10%
- 3D cell models: 5%
- Cellular phenotypic: 5%
- RNA scope analysis: 5%
- Capability: 3%
- Guided acquisition approach: 7%
- Support: 7%
- Warrantee and maintenance package: 7%
- Innovation: 3%
- Fast live imaging: 5%
- price: 30%
Published award criteria (13)
- Delivery: 3
- Detailed Specification: 10
- Imaging workflow, visualization, and image analysis: 10
- 3D cell models: 5
- Cellular phenotypic: 5
- RNA scope analysis: 5
- Capability: 3
- Guided acquisition approach: 7
- Support: 7
- Warrantee and maintenance package: 7
- Innovation: 3
- Fast live imaging: 5
- Price: 30
- Price carries 30 of 100 points: a 10% discount moves about 3 points. The method statement decides this lot, not the discount.
Price arithmetic assumes straight proportional scoring; the tender pack may use another formula.
Procedure terms & legal framework
From the official record- Procedure method
- Open procedure
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Competitive procedure
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- No (one-off requirement)
- First published
- 2 Sept 2022, 13:52 BST
- Last source update
- 23 May 2023, 17:13 BST
- Award evaluation window
- 21 Nov 2022 – …
- FTS notice number
2023/S 000-014693- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-03655cFind a Tender
How it was run
Official notice- Submission deadline
- 21 Nov 2022, 12:00 GMT
- Submission channel
- {"electronicSubmission","written"}
- Accepted languages
- en
- Bids opened
- 21 Nov 2022, 12:01 GMT
Timeline
1 Oct 2022 → 23 May 2023 · 4 dates- Next notice expected1 Oct 2022, 00:00 BST
- Submission deadline21 Nov 2022, 12:00 GMT
- Bids opened21 Nov 2022, 12:01 GMT
- Notice published23 May 2023, 17:13 BST
Notice history
5 events · 3 releases on Find a Tender · since 31 Oct 2022- Published value published: £750,00031 Oct 2022, 11:29 GMT
- Status changed to active31 Oct 2022, 11:29 GMT
- Procurement method changed31 Oct 2022, 11:29 GMT
- Deadline published: 21 Nov 2022, 12:00 GMT31 Oct 2022, 11:29 GMT
- Status changed to complete23 May 2023, 17:13 BST
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| Revvity (UK) Ltd. | £911,965 † | — | Awarded |
Contracts
Contract 014693-2023-1 · Revvity (UK) Ltd.
- Signed
- 28 Feb 2023
- Value
- £911,965
- Status
- active
Bid statistics published by the authority
| Bids | SME | VCSE | Valid bid range |
|---|---|---|---|
| 2bids | — | — | — |
Contracting authority & participating public bodies
Dispute resolution & review bodies
- Medicines Discovery CatapultReview body
Bidders & participating suppliers
1 commercial party on the notice- Perkin Elmer LAS (UK) LIMITEDAwarded supplier
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.